Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.56 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.51 |
| ▸ | CCKAR | P32238 | 3/20 | 0.51 |
| ▸ | CCKBR | P32239 | 3/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799924 | 0.93 | BACE1 (0.60) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL30799965 | 0.92 | BACE1 (0.61) | BACE1OPRD1BACE2CTSDPTPN1 | |
| SCHEMBL30799478 | 0.90 | BACE1 (0.66) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL30799955 | 0.90 | BACE1 (0.57) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL30799799 | 0.90 | BACE1 (0.66) | BACE1BACE2CTSDPTPN1 | |
| SCHEMBL30799539 | 0.90 | BACE1 (0.64) | BACE1OPRD1BACE2CTSDPTPN1 | |
| SCHEMBL30799734 | 0.90 | BACE1 (0.58) | BACE1OPRD1BACE2CTSDOPRM1 | |
| SCHEMBL30799650 | 0.89 | OPRD1 (0.55) | BACE1RENOPRD1CCKARCCKBR | |
| SCHEMBL31612153 | 0.88 | BACE1 (0.55) | BACE1BACE2CTSD | |
| SCHEMBL29447711 | 0.88 | BACE1 (0.55) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | BACE1 10/4885REN 818/4885OPRD1 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.